Global Glucagon-Like Peptide-1 (GLP-1) Receptor agonists Market Size, Share & Trends Analysis Report by Drug Type (Exenatide (Bydureon, Byetta), LiraglutidE (Victoza), Lixisenatide (Lyxumia), and Dulaglutide (Trulicity)) Forecast Period (2020-2026).
The GLP-1 receptor agonists market is anticipated to showcase a considerable growth rate during the forecast period. The rising prevalence of type 2 diabetes across the globe is a key factor contributing to the growth of the global GLP-1 receptor agonists market. According to the International Diabetes Federation (IDF), diabetes is responsible for nearly760 billion in health expenditure in 2019 that resembles 10% of total spending on adults for their health treatment. In 2019, 374 million people are observed to be at an increased risk of developing type 2 diabetes.
The GLP-1 receptor agonists market is segmented on the basis of drug type. Based on drug type, the GLP-1 receptor agonists market is segmented into Exenatide (Bydureon, Byetta), LiraglutidE (Victoza), Lixisenatide (Lyxumia), and Dulaglutide (Trulicity). Based on the drug type, Dulaglutide is anticipated to hold major market share during the forecast period. The benefits that this medication offers such as relief in diabetes and cardiovascular disorders are the key factors contributing to the growth of this market segment.
Geographically, the market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America is anticipated to hold a considerable market share in the GLP-1 receptor agonists market due to the high awareness of the drugs for the treatment of type 2 diabetes in the region. Asia-Pacific is the fastest-growing region in the GLP-1 receptor agonists market. The increasing prevalence of diabetes in the emerging economies of Asia-Pacific is a key factor contributing to the growth of the market in the region.
The Key players of GLP-1 receptor agonists market include Bristol Mayer Squibb, Novo Nordisk A/S, Sanofi SA, Eli Lilly & Company, AstraZeneca PLC, and Merck & Co., Inc. The major players of the GLP-1 receptor agonists market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are driving the growth of the global GLP-1 receptor agonists market.
Research Methodology:
The market study of the global GLP-1 receptor agonists market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in the reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. Global GLP-1 receptor agonists Market Research And Analysis By Drug Type
The Report Covers:
The GLP-1 receptor agonists market is anticipated to showcase a considerable growth rate during the forecast period. The rising prevalence of type 2 diabetes across the globe is a key factor contributing to the growth of the global GLP-1 receptor agonists market. According to the International Diabetes Federation (IDF), diabetes is responsible for nearly760 billion in health expenditure in 2019 that resembles 10% of total spending on adults for their health treatment. In 2019, 374 million people are observed to be at an increased risk of developing type 2 diabetes.
The GLP-1 receptor agonists market is segmented on the basis of drug type. Based on drug type, the GLP-1 receptor agonists market is segmented into Exenatide (Bydureon, Byetta), LiraglutidE (Victoza), Lixisenatide (Lyxumia), and Dulaglutide (Trulicity). Based on the drug type, Dulaglutide is anticipated to hold major market share during the forecast period. The benefits that this medication offers such as relief in diabetes and cardiovascular disorders are the key factors contributing to the growth of this market segment.
Geographically, the market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America is anticipated to hold a considerable market share in the GLP-1 receptor agonists market due to the high awareness of the drugs for the treatment of type 2 diabetes in the region. Asia-Pacific is the fastest-growing region in the GLP-1 receptor agonists market. The increasing prevalence of diabetes in the emerging economies of Asia-Pacific is a key factor contributing to the growth of the market in the region.
The Key players of GLP-1 receptor agonists market include Bristol Mayer Squibb, Novo Nordisk A/S, Sanofi SA, Eli Lilly & Company, AstraZeneca PLC, and Merck & Co., Inc. The major players of the GLP-1 receptor agonists market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are driving the growth of the global GLP-1 receptor agonists market.
Research Methodology:
The market study of the global GLP-1 receptor agonists market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. Global GLP-1 receptor agonists Market Research And Analysis By Drug Type
The Report Covers:
- Comprehensive research methodology of the global GLP-1 receptor agonists market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global GLP-1 receptor agonists market.
- Insights about market determinants which are stimulating the global GLP-1 receptor agonists market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- AstraZeneca PLC
- Bristol Mayer Squibb, Co.
- Eli Lilly & Company
- Merck & Co., Inc.
- Novo Nordisk A/S
- Sanofi SA
